Publication

Identification of a Molecular Activator for Insulin Receptor with Potent Anti-diabetic Effects

Downloadable Content

Persistent URL
Last modified
  • 02/20/2025
Type of Material
Authors
    Kunyan He, Emory UniversityChi Bun Chan, Emory UniversityXia Liu, Emory UniversityYonghui Jia, Harvard Medical School and Children's HospitalHongbo R. Luo, Harvard Medical School and Children's HospitalStefan A. France, Georgia Institute of TechnologyYang Liu, Georgia State UniversityW. David Wilson, Georgia State UniversityKeqiang Ye, Emory University
Language
  • English
Date
  • 2011-10-28
Publisher
  • American Society for Biochemistry and Molecular Biology
Publication Version
Copyright Statement
  • © 2011 by The American Society for Biochemistry and Molecular Biology, Inc.
Final Published Version (URL)
Title of Journal or Parent Work
Volume
  • 286
Issue
  • 43
Start Page
  • 37379
End Page
  • 37388
Grant/Funding Information
  • This work was supported, in whole or in part, by National Institutes of Health Grant CA127119 from NCI (to K. Y.).
Abstract
  • Insulin exerts its actions through the insulin receptor (IR) and plays an essential role in diabetes. The inconvenient daily injection and undesirable side-effects associated with insulin injection demand novel drugs for the diseases. To search for bioactive insulin mimetics, we developed an in vitro screening assay using phospho-IR ELISA. After screening the small molecule chemical libraries, we have obtained a compound (5,8-diacetyloxy-2,3-dichloro-1,4-naphthoquinone) that provokes IR activation by directly binding to the receptor kinase domain to trigger its kinase activity at micromolar concentrations. This compound selectively activates IR but not other receptors and sensitizes insulin's action. Moreover, it elevates glucose uptake in adipocytes and has oral hypoglycemic effect in wild-type C57BL/6J mice and db/db and ob/ob mice without demonstrable toxicity. Hence, this promising compound mimics the biological functions of insulin and is useful for further drug development for diabetes treatment.
Author Notes
  • To whom correspondence may be addressed: Dept. of Pathology and Laboratory medicine, Emory University School of Medicine, Atlanta, GA 30322. Tel.: 404-712-2814; Fax: 404-712-2979; E-mail: cbchan@emory.edu.
Keywords
Research Categories
  • Health Sciences, Pathology

Tools

Relations

In Collection:

Items